When was Stalevo approved by the FDA?

Written by Ana de Barros, PhD |

A

When was Stalevo approved by the FDA?

Category: Stalevo

The U.S. Food and Drug Administration approved Stalevo in June 2003 to treat people with Parkinson’s disease. Indications include the use of Stalevo for patients already on levodopa/carbidopa plus entacapone as separate medications, as well as its administration as a replacement treatment for people experiencing motor fluctuations despite being on optimal carbidopa/levodopa therapy.

Ana de Barros, PhD avatar

About the Author

Ana de Barros, PhD Ana holds a PhD in immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. Ana was awarded two FCT fellowships and has won the Portuguese Immunology Society Best Paper and Best Poster award in 2009 and 2010, as well as the CESPU International Research Award in 2010. After leaving the lab to pursue a career in science communication, she served as the director of science communication at iMM Lisbon.


Recommended reading